PF-3758309 is an orally available, potent and reversible PAK4 ATP-competitive inhibitor, which has been reported that it can inhibit tumor cell anchorage-independent growth, induce tumor cell apoptosis, and inhibit tumor cell proliferation (Murray et al., 2010). This evidence concerns the gene PAK4 and neoplasm.